Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North Carolina.
The latest manufacturing investment will support the ongoing development of Biogen’s late-stage clinical pipeline.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Since its establishment in 1995, the company’s manufacturing in RTP has been crucial in providing innovative treatments to millions of patients globally.
The company has invested $10bn in its North Carolina manufacturing, and plans to enhance its investments in various modalities and facilities at its two campuses in RTP.
These funds will involve expanding its antisense oligonucleotide (ASO) capabilities and infrastructure, developing multi-platform fill-finish capabilities for clinical and commercial use, and further modernising manufacturing technologies and controls through AI and advanced automation.
Biogen pharmaceutical operations and technology head Nicole Murphy stated: “We are proud of our longstanding commitment to manufacturing innovation, investment and collaboration with the Research Triangle Park community.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Our manufacturing footprint in the US has played a critical role in Biogen’s history and success, and in advancing the treatments that are making an impact for patients, families and communities here in the US and around the world.
“With this investment, we will modernise and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated community of life sciences talent in North Carolina.”
More than 90% of the advanced commercial medicines developed by Biogen undergo manufacturing and quality control testing in the US.
In May 2025, Biogen and City Therapeutics collaborated to develop RNA interference (RNAi) therapy.
Biogen agreed to pay City Therapeutics $46m: $16m upfront and $30m investment in the form of a convertible note.
